Navigation Links
Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
Date:5/20/2008

Placebo-Controlled Study Results Published in May 20 Issue of Neurology

WOODCLIFF LAKE, N.J., May 20 /PRNewswire/ -- Eisai Corporation of North America announced today the publication of a placebo-controlled study in Neurology that found patients with Lennox-Gastaut syndrome (LGS) treated with the investigational antiepileptic agent rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo (increase of 1.4%). The differences between rufinamide and placebo were observed as early as week two of the study. LGS is a severe form of generalized epilepsy that develops in early childhood and is characterized by multiple types of treatment-resistant seizures and high rates of seizure-related injury.

"Lennox-Gastaut syndrome is a devastating form of pediatric epilepsy usually resulting in multiple seizures occurring several times a day and is often associated with impaired mental development," said the study's lead author Tracy Glauser, MD, Director, Comprehensive Epilepsy Program, Cincinnati Children's Hospital Medical Center, Ohio. "Existing antiepileptics offer limited seizure control and there may be difficulties with tolerability."

Study Methods

The study was a multicenter, double-blind, placebo-controlled, randomized, parallel-group study. Male and female patients (between 4 and 30 years of age) were included if they had a diagnosis of inadequately controlled seizures associated with LGS (including both atypical absence seizures and drop attacks) and were being treated with 1 to 3 concomitant stable dose antiepileptic drugs (AEDs). Each patient must have had at least 90 seizures in the 28-day baseline period prior to study entry. One hundred thirty-nine eligible patients were randomized; 138 patients received either rufinamide (titrated up to 45mg/kg per day) (n=74) or placebo (n=64) in addition to their other AEDs.

The median percentage reduction in total seizure frequency fr
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
3. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
4. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
5. Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile
6. Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile
7. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
8. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... July 22, 2014 WuXi PharmaTech (Cayman) Inc. (NYSE: ... device R&D outsourcing company with operations in China ... today announced that it will release financial results for the ... closes on Wednesday, August 13, 2014 (which will be Thursday ... be available on the investor relations section of the Company,s ...
(Date:7/22/2014)... 22, 2014  Pressure BioSciences, Inc. (OTCQB: ... Genomics ("Parabase"), (together "the companies"), today announced ... and development agreement (the "collaboration"). Under the ... a front-end, sample preparation method for Parabase,s ... testing process. The sample preparation method will ...
(Date:7/22/2014)... New York , July 22, ... Neue Partnerschaft für umfassenden Schutz von ... in Österreich    Equashield ... von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) für ... , einen Vertriebshändler und Hersteller von ...
Breaking Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2014 Earnings Release 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2
(Date:7/22/2014)... Plate Club you eat pretty much everything you put ... Cornell University study shows that the average adult eats 92% ... plate. "If you put it on your plate, ... of the forthcoming book, Slim by Design, Professor of Marketing ... Wansink and co-author Katherine Abowd Johnson analyzed 1179 diners and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Legislation ... Seniors Access to Local Pharmacies Act of 2014”) ... Part D would undermine the availability of lower ... by $21 billion over the next 10 years, ... released by the Pharmaceutical Care Management Association (PCMA). ...
(Date:7/22/2014)... New Rochelle, NY -- New guidelines on cholesterol treatment ... least double the risk of dying from atherosclerotic cardiovascular ... as do women with a similar risk profile (based ... levels). The implications of this finding for when and ... an Editorial in Journal of Men,s Health , ...
(Date:7/22/2014)... July 22, 2014 The Pennsylvania ... ) in the Philadelphia Court of ... punitive damages in cases alleging the medication caused ... Liebhard LLP reports. In an Order dated July ... plaintiffs’ request to certify the matter for an ...
(Date:7/22/2014)... News) -- One of the largest studies ever conducted ... uncovered 83 new sites on chromosomes that harbor inherited ... an international team of researchers, now bring the total ... to 108. Although these schizophrenia-associated genes aren,t ... predict who will or will not develop the illness, ...
Breaking Medicine News(10 mins):Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Gene Discoveries Could Shed New Light on Schizophrenia 2
... Edward G.,Rendell today issued an executive order regarding ... closed after the law,authorizing its operation expired on ... 2003, when PHC4 was allowed to "sunset",by the ... action., The Rendell administration is committed to ...
... Illinois at Chicago is one of 11 centers in ... in the Clinical Islet Transplant Consortium funded by the ... clinical studies to test new approaches to islet transplantation ... effects for adults with difficult-to-control type 1 diabetes. , ...
... to vote soon on legislation that would cut ... WASHINGTON, July 8 Seniors across,Pennsylvania are speaking ... in legislation being considered in the U.S. Senate. ... the Medicare Advantage,program in Pennsylvania alone and severely ...
... DETROIT, July 8 The Barbara Ann Karmanos,Cancer ... with Meadowbrook C,Management, LLC, to lease space and ... Michigan. The approximately 14,000 square foot,space will allow ... in Novi,and the surrounding communities, as well as ...
... cancer research, particularly in observational epidemiology studies. The ... mitigated if researchers use more exacting standards when ... in the July 8 online issue of the ... Additionally, the impact of false-positive results could be ...
... in Iron Blood Levels Associated with Decreased Cancer Risk in ... arterial disease who participated in a randomized controlled trial in ... a reduced incidence of cancer relative to men in the ... have suggested that lower levels of iron in the blood ...
Cached Medicine News:Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 2Health News:Governor Rendell Issues Executive Order Regarding Pennsylvania Health Care Cost Containment Council 3Health News:UIC in NIH-funded islet transplantation study for type 1 diabetes 2Health News:Pennsylvania Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Karmanos Cancer Center Partners With Meadowbrook to Expand Outreach and Access for Cancer Services 2Health News:Awareness of epidemiology's limitations could reduce impact of false-positive cancer results 2Health News:Also in the July 8 JNCI 2Health News:Also in the July 8 JNCI 3Health News:Also in the July 8 JNCI 4
For the quantitative in vitro determination of Transferrin in Serum...
Determination of Reptilase Time.Extracted venom of Bothrops atrox. 20 BU (Batroxobin unit) per vial....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: